Obstructive sleep apnea is a condition in which the airway repeatedly collapses or narrows during sleep, interrupting breathing and reducing blood oxygen. It is extremely common in older adults, yet a review published in the journal Drugs and Aging points out something counterintuitive: older patients often show fewer obvious symptoms than younger ones. That mismatch makes the condition harder to catch, harder to diagnose, and harder to manage.
The standard treatment, continuous positive airway pressure, or CPAP, pushes a steady stream of air through a mask to keep the airway open. CPAP remains the recommended first step, but the review authors note that its benefits in older populations are not clearly established, and many patients simply refuse to use it. That gap has pushed researchers to ask whether medications might fill some of the space CPAP leaves behind.
The review maps out several pharmacologic approaches that are currently under investigation. Each one targets a different part of the biological chain that leads to airway collapse, and each carries its own set of tradeoffs. Understanding how researchers are thinking about these options gives useful context for anyone trying to follow the science.
Why older adults are a distinct population
The review opens by explaining that older patients present diagnostic challenges that do not apply as strongly to younger groups. Standard screening questionnaires lose specificity with age, meaning they generate more false results in either direction. At the same time, the gold-standard diagnostic test, polysomnography, which involves sleeping overnight in a monitored lab, is harder for older adults to attend because of mobility, health conditions, and access issues.
Biologically, the pattern of sleep apnea also shifts with age. The underlying causes of airway collapse involve a mix of factors including muscle tone around the throat, the sensitivity of the respiratory control system in the brain, and how much fatty tissue surrounds the upper airway. Each of these shifts with aging, which means the same drug that works well in a middle-aged person may behave very differently in someone decades older.
GLP-1 receptor agonists and airway fat
One of the more prominent findings highlighted in the review involves glucagon-like peptide-1 receptor agonists, a class of peptide-based compounds that act on receptors originally identified for their role in blood sugar regulation. The review singles out tirzepatide, a dual-acting agent in this class, as showing meaningful improvements in several sleep apnea measures. Specifically, researchers studying the compound observed reductions in the apnea-hypopnea index, which counts the number of breathing interruptions per hour, reductions in hypoxic burden, which reflects how often and how deeply blood oxygen falls, and improvements in overall sleep outcomes.
The proposed mechanism is fairly straightforward: these compounds appear to reduce fat deposited around the upper airway. Less fat around the throat means less external pressure on the airway walls, making collapse less likely. The review describes results as well-tolerated in the populations studied. That tolerability profile matters considerably in older adults, where side effects from any medication carry greater weight.
Noradrenergic and antimuscarinic combinations
A second pharmacologic approach combines two mechanisms in a single regimen. Noradrenergic agents increase the activity of neurons that use noradrenaline as a signaling molecule, which can tighten the muscles that dilate the pharynx, the cavity at the back of the throat above the airway. Antimuscarinic agents work by blocking certain signals that would otherwise reduce muscle activity in that region.
The review reports that this combination has produced significant reductions in the apnea-hypopnea index and improvements in overnight oxygen saturation in published studies. The underlying idea is that if the muscles surrounding the upper airway maintain better tone through the night, they resist the collapse that interrupts breathing.
However, the review flags a serious concern for older patients specifically. Antimuscarinic drugs belong to a broader chemical class known as anticholinergic agents, and this class is associated with cognitive side effects, confusion, urinary retention, and falls in older adults. The review describes these risks as high in this population, which tempers enthusiasm for the combination despite its demonstrated effects on airway mechanics.
Serotonergic, cholinergic, and sedative approaches
The review also covers agents that work through serotonin and acetylcholine signaling pathways. Both neurotransmitter systems influence pharyngeal muscle tone, and the logic is similar to the noradrenergic approach: changing chemical signaling in the brainstem and throat muscles might keep the airway more stable during sleep.
The authors are cautious here. The studies examined were generally small, and results have been inconsistent across different research groups. The review characterizes the evidence base as limited by sample sizes, methodology differences, and conflicting findings. Early data points at a potential role for these agents, but no firm conclusions are available yet.
Sedative-hypnotic drugs, meaning compounds that promote sleep or reduce arousals from sleep, represent a different angle entirely. Rather than targeting the airway directly, they work on how the brain responds to disrupted breathing. Some research suggests they may raise the arousal threshold, meaning the brain does not wake as often in response to airway events. The review notes this may improve sleep quality in some measures, but also flags risks of central nervous system depression in older adults, including excessive sedation and falls.
Sulthiame and carbonic anhydrase inhibition
One compound the review highlights as particularly promising is sulthiame, a carbonic anhydrase inhibitor. Carbonic anhydrase is an enzyme involved in regulating carbon dioxide levels in the blood, and inhibiting it shifts the chemistry of respiratory control in ways that appear to stabilize breathing during sleep.
The review describes dose-dependent improvements in sleep apnea severity with sulthiame, meaning that higher doses produced larger effects in the studies examined. Tolerability was reported as well-maintained in the populations studied. The mechanism is distinct from the other approaches discussed, which gives it a different safety and efficacy profile and potentially makes it useful in patients where other options are not suitable.
The larger picture for research
The review closes by noting that older adults represent a population with genuinely distinct biology, distinct diagnostic challenges, and distinct risks from the side effects of any medication. The authors argue that pharmacotherapy for sleep apnea in this group needs dedicated study rather than extrapolation from trials conducted mostly in younger patients.
No single drug class emerges from the review as a clear winner. Instead, the picture is of several promising mechanisms, each supported by varying degrees of evidence and each carrying different safety considerations. GLP-1 receptor agonists and sulthiame appear to have the most favorable current evidence profiles in terms of balancing efficacy with tolerability in older adults, but the authors are explicit that more age-specific data is needed before strong conclusions can be drawn.
For anyone following the research landscape on sleep, metabolism, and airway biology, this review serves as a useful map of where the science currently stands and where the remaining questions are concentrated.
